Study S000313
Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial
Registration
Registered primary outcomes
- Proportion of participants with recurrent hypertriglyceridemia-induced acute pancreatitis [Within 18 months after randomization]
Linked records (18)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0004112 | Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study. Nassar M, Diabetes & metabolic syndrome | 2024 | Nonrandomized study | PMID 39332263DOI | registry reference BACKGROUND:39332263 |
| R0005285 | GLP-1 agonists: A review for emergency clinicians. Long B, The American journal of emergency medicine | 2024 | Narrative review | PMID 38241775DOI | registry reference BACKGROUND:38241775 |
| R0006635 | Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials. Yang W, Obesity reviews : an official journal of the International Association for the Study of Obesity | 2024 | Systematic review | PMID 38346789DOI | registry reference BACKGROUND:38346789 |
| R0004775 | Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. Sodhi M, JAMA | 2023 | Nonrandomized study | PMID 37796527DOI | registry reference BACKGROUND:37796527 |
| R0004491 | Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Liu L, Frontiers in endocrinology | 2022 | Nonrandomized study | PMID 36568085DOI | registry reference BACKGROUND:36568085 |
| R0005549 | Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. He L, JAMA internal medicine | 2022 | Systematic review | PMID 35344001DOI | registry reference BACKGROUND:35344001 |
| R0006087 | Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Ard J, Advances in therapy | 2021 | Narrative review | PMID 33977495DOI | registry reference BACKGROUND:33977495 |
| R0007621 | Safety of Semaglutide. Smits MM, Frontiers in endocrinology | 2021 | Nonrandomized study | PMID 34305810DOI | registry reference BACKGROUND:34305810 |
| R0023399 | Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH, The New England journal of medicine | 2021 | Randomized trial | PMID 33567185DOI | registry reference BACKGROUND:33567185 |
| R0010007 | Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials. Nreu B, Diabetes research and clinical practice | 2020 | Systematic review | PMID 32084455DOI | registry reference BACKGROUND:32084455 |
| R0019748 | Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Abd El Aziz M, Diabetes, obesity & metabolism | 2020 | Systematic review | PMID 31750601DOI | registry reference BACKGROUND:31750601 |
| R0025109 | Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Hjerpsted JB, Diabetes, obesity & metabolism | 2018 | Randomized trial | PMID 28941314DOI | registry reference BACKGROUND:28941314 |
| R0007416 | Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Monami M, Diabetes, obesity & metabolism | 2017 | Systematic review | PMID 28244632DOI | registry reference BACKGROUND:28244632 |
| R0012184 | Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. Nauck MA, Diabetes care | 2017 | Other trial | PMID 28283565DOI | registry reference BACKGROUND:28283565 |
| R0025365 | Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Steinberg WM, Diabetes care | 2017 | Randomized trial | PMID 28473337DOI | registry reference BACKGROUND:28473337 |
| R0025434 | Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Steinberg WM, Diabetes care | 2017 | Randomized trial | PMID 28476871DOI | registry reference BACKGROUND:28476871 |
| R0022927 | A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Pi-Sunyer X, The New England journal of medicine | 2015 | Randomized trial | PMID 26132939DOI | registry reference BACKGROUND:26132939 |
| R0027633 | Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. Singh S, JAMA internal medicine | 2013 | Nonrandomized study | PMID 23440284DOI | registry reference BACKGROUND:23440284 |